Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

The COVID-19 vaccine and treatment maker said early Monday that it will pay $47.50 per share in cash for each Metsera share. That represents a premium of more than 42% to Metsera’s closing price Friday. Pfizer also could pay an additional $22.50 per share depending on how Metsera’s product pipeline...

Redirecting to full article...